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Abstract: 3-Alkyl pyridinium alkaloids (3-APAs) are common secondary metabolites in 
marine sponges of the order Haplosclerida. In recent years, our laboratory has isolated and 
synthesized several new members of this family such as haliclamines C–F, viscosamine, 
viscosaline and a cyclic monomer. All of them were isolated from the Arctic sponge 
Haliclona viscosa collected in Spitsbergen, Norway. In this article we report the syntheses 
of these secondary metabolites from Haliclona viscosa and related compounds and give a 
short overview of the bioactivity. 
 
Keywords:  3-alkyl pyridinium alkaloids; Haliclona viscosa; synthesis; marine natural 
products 
 
1. Introduction 
 
The marine sponge Haliclona viscosa inhabits Arctic waters and the North Sea. In the European 
region it is most common around the British Isles up to Spitsbergen, Norway, but can also be found in 
some regions of the French and Belgian coasts. Secondary metabolites of this sponge are active in 
biological tests for antibacterial [1], antifungal [2], cytotoxic [2], and feeding deterrent [3] compounds. 
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2. Natural Products from Haliclona viscosa 
 
A large number of 3-APAs have been isolated from marine organisms, especially from sponges of 
the order Haplosclerida (mainly from the genus Haliclona). Although 3-APAs look structurally quite 
simple, the structure elucidation by NMR spectroscopy is complicated by the fact that most of the 
methylene groups in the alkyl chains show the same chemical shift. Therefore, the 3-APAs are an ideal 
test case for a combined approach of NMR spectroscopy and mass spectrometry. In the NMR spectrum 
only the positions 1, 2, n-1, and n of the alkyl chain can be differentiated. Information about the length 
of the alkyl chain is only available from MS/MS spectra. 
In samples of Haliclona viscosa, which were collected between 1999 and 2003, several new 
secondary metabolites – viscosaline (1), haliclamines C–F (2–5), the known cyclostellettamine C 
(Figure 4, 23), a cyclic monomer (6) and the trimer viscosamine (7) (all Figure 1) – were isolated and 
identified by NMR and MS methods. 
 
Figure 1. Structures of new natural products 1–7 isolated from Haliclona viscosa. 
 
 
All of these compounds are characterised by six-membered azacycles, which are connected to alkyl 
chains at position 1 and/or 3. Regardless of the oxidation state of the six-membered ring, we classify 
these compounds as 3-APAs since most of the rings possess a pyridine or pyridinium structure. The  
3-APAs can be divided into two main groups: (a) linear (Section 2.1) and (b) cyclic compounds   
(Section 2.2). These groups can be further distinguished by the number of six-membered azacycles in 
one molecule, e.g., monomer, dimer, trimer and so on. 
 
2.1. Linear 3-APAs 
 
The majority of the isolated compounds of the 3-APA family belong to the group of the linear 
monomers. In comparison with other groups the linear monomers exhibit a broader constitutional 
variety. Their alkyl chain length varies from twelve to eighteen methylene units; double and triple 
bonds as well as a nitrogen based functional group are common features. Examples of linear 3-APAs 
are: niphatynes A (8) and B (9)  [4], niphatesins A (10) and G (11)  [5,6] (all isolated from   
Niphates  sp.) and ikimines A (12) and D (13)  [7] isolated from an unidentified sponge from 
Micronesia (see Figure 2). Mar. Drugs 2010, 8                        
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Figure 2. Linear and monomeric 3-alkyl pyridinium alkaloids 8–13. 
 
 
With the increasing number of monomeric units within the 3-APAs, the chemical diversity and the 
size of the attached functional groups decreases. Examples include pachychalines A (14) and C 
(15) [8], both isolated from Pachychalina sp., niphatoxins A (16) and B (17) [9], and viscosaline (1, 
Figure 1) isolated from Haliclona viscosa  [10]. Even larger members are the halitoxins (18) [11], 
isolated from a Haliclona species and the synthetic linear oligomer 19 [12] (see Figure 3). The dimer 
viscosaline (1) was the first 3-APA linked to an amino acid moiety isolated from natural sources. 
 
Figure 3. Chemical structures of linear and oligomeric 3-APAs 14–19. 
 
 
The connectivity of the monomeric units within the di- and trimers is not necessarily head/tail (as in 
the natural products from Haliclona viscosa), as head/head and tail/tail linked dimers are known. The 
linear 3-APAs that are shown in Figure 3 are either purely head/tail linked [e.g., pachychaline A (14) 
or the halitoxins (18)] or a mixture of head/tail and tail/tail connected units [e.g., pachychaline C (15) 
and niphatoxins A (16) or B (17)]. The synthetic isocyclostellettamines (see Scheme 7) can be 
regarded as head/head and tail/tail linked isomers of the naturally occuring cyclostellettamines. Mar. Drugs 2010, 8                        
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2.2. Cyclic 3-APAs 
 
The above-mentioned simplification of the chemical structure is also observed for cyclic 3-APAs. 
Next to the azacycles, double bonds are the only functionality observed in cyclic 3-APAs. A secondary 
metabolite isolated from Haliclona viscosa is the only naturally occuring cyclic monomer (6) which 
represents the smallest member of the cyclic 3-APAs macrocycles [13–15]. Prior to its isolation these 
molecules have been observed as side products in the synthesis of cyclostellettamines [13,14]. 
 
Figure 4. Chemical structures of cyclic 3-APAs. 
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Dimeric macrocycles dominate the group of the cyclic 3-APAs. They lack side chains and the 
azacycles share the same oxidation state, but the length of the alkyl chains as well as the number of 
double bonds in one chain may vary. Most pyridinium salts or cyclostellettamines (A–F, 21–26) [16] 
carry no double bonds with the exception of the dehydrocyclostellettamines D and E isolated by 
Fusetani  et al. [17]. Further cyclostellettamines (G–L) were isolated from sponges of the genera 
Xestospongia [17]  and  Pachychalina  [18]. The corresponding tetrahydropyridine compounds are Mar. Drugs 2010, 8                        
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called haliclamines (2–5 and 27, 28) [2,19–22]. Haliclamines A (27) and B (28) have two and three 
double bonds within the alkyl chains  [2], respectively, whereas haliclamines C–F (2–5) lack 
unsaturation in the alkyl chains. 
There are only two reports of 3-APA macrocycles with three or more monomeric units from natural 
sources. Teruya et al. isolated a mixture of di- to hexamers of 3-dec-3-enpyridines and named them 
cyclohaliclonamines [23]. Our group isolated and synthesized the cyclic trimer viscosamine (7) [24]. 
The other macrocycles are synthetic compounds such as the tetrapyridinium macrocycle (29) [25] or 
even larger macrocycles (i.e., 30) [14]. Representatives are shown in Figure 4. 
 
3. Biological Activity 
 
Our interest in the sponge Haliclona viscosa was raised some years ago during a general 
investigation on invertebrates from Spitsbergen in which 18 abundant sessile or slow-moving species 
were studied with respect to their feeding deterrence and antimicrobial activity  [3,10,26–28]. The 
feeding deterrence was tested against the amphipod Anonyx nugax (a common predator in Spitsbergen) 
and the starfish Asterias rubens from the North Sea  [3,26,27]. Only two of the 18 crude extracts 
(Haliclona viscosa and the actinian Hormathia nodosa) showed significant activity in the feeding 
deterrence assay. After fractionation of the crude extract of Haliclona viscosa only the n-hexane  
(P = 0.02) and n-butanol fractions (P < 0.01) were significantly deterrent against Anonyx nugax. The 
remaining water fraction caused no effect. Testing of the pure compounds revealed that only one 
compound from the n-hexane fraction (P < 0.01) and one compound from the n-butanol fraction   
(P < 0.01) were active. The n-butanol fraction contains the 3-APAs. The active component was 
identified as viscosaline (1) whereas haliclamine C (2, P = 0.58) and haliclamine D (3, P = 0.24) were 
not active. In the star fish assay only the crude extract of the sponge Haliclona viscosa was feeding 
deterrent, whereas no activity was observed for the other crude extracts. 
For the investigation of the antimicrobial activity five bacterial strains were isolated from the 
vicinity of the sponge. The crude extract of Haliclona viscosa showed a very strong activity against all 
five bacteria  [28]. Three crude extracts from the soft coral Gersemia rubiformis, the bryozoan 
Alcyonidium gelatinosum, and the nudibranch Flabellina salmonacea inhibited the growth of two 
bacterial strains whereas the extract of Hormathia nodosa showed no activity at all. The n-butanol 
fraction of Haliclona viscosa still showed a strong activity against all five bacteria. No activity was 
observed for the n-hexane and water fractions. The pure compounds affected only two to four out of 
the five bacteria. Viscosaline (1) showed a moderate activity against four bacterial strains whereas the 
halicamines C and D (2 and 3) showed a very strong activity against two bacteria. Haliclamine D (3) 
also showed a weak inhibition against one further bacterial strain. 
The crude extracts and the four fractions (n-hexane, ethyl acetate, n-butanol, and water) of 
Haliclona viscosa (2000 and 2001) were also tested against 17 microorganisms [10]. Strong activities 
were only observed for the ethyl acetate and the n-butanol fractions from the specimen collected in 
2000. From the 2001 specimen, crude extracts were strongly active against four bacterial strains 
(Aquaspirillum psychrophilum, Microbacterium barkeri, Micrococcus sp., and Roseobacter litoralis), 
and bioactivity was principally due to the n-butanol fraction. Mar. Drugs 2010, 8                        
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Several pure compounds synthesized in our laboratory were further tested in antimicrobial assays 
against  Escherichia coli tolC and Staphylococcus aureus and for their cytotoxicity against mouse 
fibroblasts L929 [15]. Monomeric linear compounds without functional groups were not active at all, 
whereas linear molecules with functional groups showed a moderate activity. The strongest activity 
was observed for cyclic compounds in all three assays. 
 
4. Synthesis 
 
The main focus of our synthetic work was the preparation of cyclic 3-APAs. The combination of 
different known methods generated a synthesis scheme which allowed a module-like preparation of 
many different structures from one alkyl pyridine precursor. The syntheses of monomeric, dimeric and 
trimeric cyclic 3-APAs are conducted in three steps [29]: 
(1)  synthesis of the monomers, 
(2)  functionalisation of the monomers, and 
(3)  coupling and/or cyclisation. 
As monomeric units we synthesized 3-ω-hydroxy alkyl pyridines with varying chain lengths. The 
synthesis commenced with a dicarboxylic acid 1-I, a diol 1-II or a bromo alcohol 1-III, depending on 
their commercial availability. 
 
Scheme 1. Synthesis of different 3-ω-hydroxyalkyl pyridines with n = 3–11. 
 
 
Scheme 1 shows the synthetic strategy with the formation of the protected 3-alkyl pyridine 1-V and 
the target molecule after cleavage of the protecting group 1-VI [30,31]. The next step in the synthesis 
was the functionalisation of the monomers prior to coupling and/or cyclisation. To prepare monomeric 
cyclic 3-APAs, alcohol 1-VI was converted to a 3-ω-bromo alkyl pyridine 2-Ia (see Scheme 3). This Mar. Drugs 2010, 8                        
 
 
489
molecule reacted intramolecularly to form the target molecules (6 and 20) as shown in Scheme 2. The 
identical reaction conditions explain the fact that monomeric cyclic 3-APAs also occur as side 
products within the synthesis of higher oligomeric and cyclic 3-APAs (Scheme 4, first step, reaction to 
4-I) when the ring nitrogen atom is not protected [32]. 
Scheme 2. Synthesis of monomeric cyclic 3-APAs 6 and 20. 
 
 
The syntheses of haliclamines and cyclostellettamines were carried out according to a method 
introduced by Baldwin and co-workers [32]. The monomer was activated by the conversion of the 
hydroxyl group to a halogenide (2-Ia, bromide or 2-Ib, chloride) and protected by oxidation of the ring 
nitrogen atom to form N-oxide 3-Ia/b, as shown in Scheme 3. 
Scheme 3. Functionalisation of 3-ω-hydroxyalkyl pyridines with n = 3–11 and X = Br (a) 
or X = Cl (b). 
N
OH
N
X
N
X
O
a) SOCl2, dioxane, 0°C to r.t.; ~ 70 %
or
b) HBr(aq),1 1 0 ° C ;~8 5%
m-CPBA, CH2Cl2,
0°C to r.t.
~9 5%
n
n n
(1-VI)
(2-Ia/b) (3-Ia/b)  
 
In the next step, the activated and protected molecule 3-Ia/b was coupled with another   
3-ω-hydroxyalkyl pyridine 1–VI. To enhance coupling effiency during the dimerisation 3-Ia/b was 
further activated by conversion to an iodide in an in situ Finkelstein substitution of chloride or 
bromide. Deprotection and activation of the resulting dimer took place in a single step prior to 
cyclisation. Cyclisation to form the cyclostellettamines 4-II was carried out under pseudo high dilution 
conditions and required no further isolation or purification of the activated dimer. In the last step the 
corresponding haliclamines 4-III were obtained by reduction with sodium borohydride (Scheme 4). 
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Scheme 4. Synthesis of cyclostellettamines and haliclamines (X = Cl or Br, n = 3–11, m = n – 1). 
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n
m
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In the synthesis of 3-APA dimers and trimers, the key step is the coupling of the monomers, which 
must be functionalised depending on the chosen method. The most straightforward approach is the use 
of the pyridine nitrogen as a nucleophile in a substitution reaction, which requires an electrophilic 
terminal carbon of the partner monomer. Its activation was achieved via introduction of a good leaving 
group. To prevent intramolecular reactions or uncontrolled oligomerisation, a suitable protecting group 
for the ring nitrogen of the electrophile had to be introduced. 
Faulkner  et al.  [25] reported a small scale one step/pot synthesis of cyclic 3-APAs without 
protecting groups using in situ activation of the monomers (Scheme 5). They were able to isolate 
monomers, dimers, trimers, and even higher oligomers via HPLC. In our group an analogous synthetic 
approach failed. We could only isolate very small quantities of dimeric 3-APAs. 
 
Scheme 5. Synthesis of 3-alkyl pyridinium macrocycles by Faulkner et al. (n = 1, 2, or 3). 
 
 
Besides the nucleophilic substitution approach, Marazano et al. [33] used the Zincke reaction of an 
amine and a dinitrophenyl pyridinium salt to generate oligomeric 3-APAs. His group also reported a 
biomimetic synthesis in which coupling was achieved via a pyridine ring formation [34]. Olefin 
metathesis as applied by Balando and co-workers  [35] and the optimized synthesis with other 
strategies of protection and deprotection [36] open further avenues for the generation of   
pyridinium macrocycles. Mar. Drugs 2010, 8                        
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In order to increase the number of monomeric units within the macrocycles, the previously 
described synthesis of cyclostellettamines was expanded as shown in Scheme 6. 
 
Scheme 6. Synthesis of viscosamine (7). 
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N
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Activation and deprotection in one step prior to cyclisation limits the synthesis by Baldwin et al. 
[32] to dimers. By using an orthogonally activated monomer, it was possible to use the advantages of 
the dimer synthesis and insert an additional monomeric unit. Dimer 6-II was prepared from N-oxide  
3-Ib and a bis-protected alkylpyridineamine like Baldwin’s cyclostellettamine precursors   
(4-I). Unlike these dimers, the amino dimer 6-II can – after cleavage of the Boc-protection group – 
react with hydroxy Zincke-salt 6-I, which was prepared in one step from protected 3-ω-hydroxyalkyl 
pyridine 1-V. The linear trimer 6-III was then deprotected, activated and cyclised to provide the target 
molecule viscosamine (7). By combining the approaches of Baldwin et al. [32] and Marazano   
et al. [33] we were able to prepare viscosamine (7) as a trimer and save one step compared to 
Marazano’s method. It also reduced the number of steps with charged oligomers, thus facilitating  
the purification. Mar. Drugs 2010, 8                        
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Scheme 7. Synthesis of isoscyclostellettamines. 
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For the synthesis of isocyclostellettamines (Scheme 7), the synthetic strategy had to be modified. 
Two variants for the preparation of isocyclostellettamines were established. Variant A starts with an  
ω-aminocarbonic acid 7-I that was first reduced to the alcohol 7-II and then protected to give 7-III. By 
reacting 7-III with an 1,ω-dipyridine alkane 7-IV, an unsymmetric and mono-alkylated 1,ω-dipyridine 
alkane 7-V was formed. Cyclisation to the target molecule was achieved via Zincke-salt 7-VI. Variant 
B started with 1,ω-dipyridine alkane 7-IV that was directly alkylated with 11-bromoundecanol to form 
1,ω-dipyridine alkane 7-VII, from which the target molecule was directly accessed. Scheme 7 shows 
the difference of the synthetic strategies via a Zincke-salt or via a nucleophilic substitution by the 
pyridine nitrogen. 
Variant B has the advantage that it is shorter than variant A and the bromoalcohol for the first 
alkylation is commercially available. Furthermore the overall yield through both variants is in variant 
B (10% over 4 steps) almost three times higher than in variant A (4% over 7 steps). But variant A 
underlines the good applicability of the Zincke-salt for the synthesis with the disadvantage of an 
additional step and lower yields. Mar. Drugs 2010, 8                        
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Scheme 8. Synthesis of viscosaline esters 32 with m, n = 9–11. 
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The synthesis of viscosaline (1) as a functionalized linear 3-APA was previously discussed as a 
module-like synthesis in order to prepare various analogs with different amino acid residues in the 
terminal position. This approach failed in numerous ways. Neither reductive amination of β-Ala 
derivatives [37] nor their alkylation with halogenalkyl pyridines [38] led to the desired molecules in 
sufficient yields. Further experiments lead to a single synthesis for a β-alanine moiety. Similar to the 
synthesis of viscosaline (1) by Baldwin et al. [39], the amino acid moiety is introduced via an aza-
Michael reaction. A 3-ω-aminoalkyl pyridine 8-I was treated with acrylonitrile and Hünig’s base and 
subsequently protected to form the alkylated and protected amine 8-II. Since 8-II is prepared from 
amino alkyl pyridine 8-I, the utilisation of 1-chloro-2,4-dinitrobenzene was an adequate and 
advantageous way to activate the pyridine ring by conversion to Zincke-salt 8-III, which was coupled 
to 3-ω-aminoalkyl pyridine 8-I at the ring nitrogen to form salt 8-IV. Finally, the remaining protecting 
group was removed and the nitrile moiety was oxidized and immediately esterified in the presence of 
methanol to the viscosaline esters (32), as shown in Scheme 8. 
 
5. Conclusions 
 
During our project a series of natural compounds and related derivatives were synthesized. Our 
synthetic effort started with the synthesis of cyclostellettamines and haliclamines according to a Mar. Drugs 2010, 8                        
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methodology described by Baldwin and co-workers. In the synthesis of viscosamine (7) we had to 
overcome the limitation to dimeric structures of Baldwin’s approach by combining it with Marazano’s 
application of the Zincke reaction. Cyclic 3-APAs with one (6, 20) or three (33) monomeric units with 
alkyl chains of different length can thus be prepared, opening a way to a library of different 3-APAs 
for further experiments. The synthesis of isoscyclostellettamines 31 provides access to material which 
can be used to deepen the understanding of the biological activities of 3-APAs. In the synthesis of 
viscosaline (1), we experienced unexpected problems in the preparation of the amino acid bearing 
alkyl pyridine. Further experiments should lead to a more general synthesis which shall provide   
3-APAs with various amino acid functionalities. Figure 5 summarizes the general structures of the 
compounds we have synthesized so far and originally isolated from the Arctic sponge   
Haliclona viscosa. 
 
Figure 5. Chemical structures of the synthesized compounds (no anions shown). 
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